Chinese Biotech Aims for U.S. Approval of Groundbreaking Cancer Therapy as Merck Faces Competition

In a bold move signaling the intense competition within the biotechnology sector, a Chinese biotech company is seeking to secure regulatory approval for its innovative cancer therapy in the United States. This development comes as Merck & Co., a leading global player in cancer treatments, faces potential competition that could disrupt its established market dominance.

Continue reading